



# **Navigating evolving pharmacovigilance requirements with Cortellis Regulatory Intelligence 30 minutes + Q&A**

Beth Wise, Claudia Haas and Emma Jourdan  
Customer Education Team

July 2025




# Agenda



- Cortellis Regulatory Intelligence
- Use case questions
- Live demo
- Coming soon: Cortellis AI Regulatory Assistant
- Feedback, wrap up, Q&A

# Cortellis: Unlock hidden insights and bring life to science

Make data-driven decisions with speed and certainty



# What is Cortellis Regulatory Intelligence?

Global regulatory information, across all functions and responsibilities



**300K+ official documents**



**8K Value-add regulatory reports, analyses and global comparisons**



**All documents have English translations**



**81 countries and regions  
Drugs & Biologic and  
75 Medical Devices & IVDs**



**Updated daily**



**Regulatory experts & local consultants**

# What will we cover today?

## Use Case 1 (Slides 8-11):

Compare pre- and post-marketing PV reporting and surveillance requirements across multiple countries.

## Use Case 2 (Slides 12-13):

Access and interpret key policy documents translated into English.

## Use Case 3 (Slides 14-15):

Monitor Risk Management Plans (RMPs) for products in the European Union and the United States.


## Use Case 4 (Slides 16-17):

Set up customized alerts to stay informed of regulatory changes.

## Coming soon: Cortellis AI Regulatory Assistant (Slides 18-27)

# Cortellis Landing Page

Click the “**Go to...**” button to access Cortellis Regulatory Intelligence.



# Cortellis Regulatory Homepage

Click the tabs to browse value-add reports (Comparison tables, Intelligence Reports, Regulatory Summaries) or start searching with Quick Search or Source Documents Search.

The screenshot displays the Cortellis Regulatory homepage. On the left is a dark sidebar with navigation icons. The main header features the 'Regulatory' title, 'Analytics Tools', and 'CMC Intelligence' tabs. A purple-bordered navigation bar contains tabs for 'All', 'Comparison Tables', 'Intelligence Reports', 'Regulatory Summaries', and 'Source Documents'. To the right of this bar are filters for 'Drugs & Biologics' and 'Medical Devices & IVDs'. Below the navigation bar is the 'Quick Search' section, which includes a search input field, a 'Search' button, and an 'Advanced search' link. A 'Filter' section below the search bar lists categories like 'Country/Region', 'Topic', 'Document Type', 'Document Category', 'Date', 'Translation Status', and 'All other filters', along with a 'Reset Filters' option. The lower-left area contains two sections: 'Ask the Expert' and 'Local Consultants'. The lower-right area features a 'Last Updates' bar chart showing data for four dates: Sep 30, Oct 07, Oct 14, and Oct 21. The chart is a stacked bar chart with four series: Reference Document (dark purple), Regulatory Summary (medium purple), Regulatory Intelligence Report (blue), and Comparison Tables (light blue). A legend on the right lists the total counts for each series. A 'Support' button is located in the bottom right corner.

**Regulatory** **Analytics Tools** **CMC Intelligence**

**All** Comparison Tables Intelligence Reports Regulatory Summaries Source Documents

**Quick Search** [View all](#)

Quick search English keywords **Search** [Advanced search](#)

**Filter**

Country/Region Topic Document Type Document Category Date Translation Status All other filters [Reset Filters](#)

**Ask the Expert**

**Local Consultants**

**Last Updates**

1,000

Sep 30 Oct 07 Oct 14 Oct 21

Total (4607)


- Comparison Tables (30)
- Regulatory Intelligence Report (119)
- Regulatory Summary (542)
- Reference Document (3916)

**Support**



# Compare incidents/adr reporting requirements across countries and regions

## Comparison Tables



The screenshot displays the Cortellis Regulatory Comparison Tables interface. The top navigation bar includes the Cortellis logo, a user name 'Beth Wise', and tabs for 'Regulatory' and 'CMC Intelligence'. The 'Regulatory' tab is active, and the 'Comparison Tables' link is highlighted in the top navigation bar. The main content area shows a list of topics under 'Pharmacovigilance and Risk Management'. The 'Post-Marketing Periodic Safety Reporting Requirements and Timeline' topic is highlighted with a red box.

**Regulatory** CMC Intelligence

All Comparison Tables Intelligence Reports Regulatory Summaries Source Documents

**Browse** Search

Drugs and Biologics Medical Devices and IVDs

► Authorities and Organizations

Health Ministry and Regulatory Agency Directory

► Legal Definitions and Marketing Requirements

Legislative/Regulatory Framework: Biosimilar Products

Legislative/Regulatory Framework: Generic Products

National Pharmaceutical Laws and Regulations Directory

National Pharmacopeia Directory

► **Pharmacovigilance and Risk Management**

Post-Marketing Expedited Reporting Requirements and Timelines

**Post-Marketing Periodic Safety Reporting Requirements and Timeline**

Pre-Marketing Expedited Reporting Requirements and Timelines

Pre-Marketing Periodic Safety Reporting Requirements and Timelines

Risk Management Submission Requirements and Qualified Person for Pharmacovigilance (QPPV) Guidance

1. Click Comparison tables
2. Scroll down to Pharmacovigilance and Risk Management (or Medical device/IVDs adverse incident reporting)
3. Select the topic of interest (e. g. Post-Marketing Periodic Safety reporting Requirements and Timelines)



# Compare incidents/adr reporting requirements across countries and regions

## Comparison Tables

1. Compare data
2. Apply Filters
3. Scroll to the right to reveal more data
4. Link to official documents and Regulatory Summaries

Last Updated Date 11-Apr-2024							
Global Comparison							
Apply Filters							
Country/Region	Requirements for submission of post-marketing periodic reports to CAs	Format/standards applicable to post-marketing periodic reports to CAs	Timelines/frequencies for submission of post-marketing periodic reports to CAs	Submission method for post-marketing periodic reports to CAs			
Algeria	For all medicinal products marketed in Algeria. Generics: PBRER not r ...	PBRER as described in Section 10-D of the Algerian PV Guidelines ...	Within 90 calendar days from the data lock point. PBRERs submission a ...	Electronic copy on a CD/DVD to: Centre National de Pharmacovigilance ...			
Argentina	All medicinal products marketed	Local format ICH E2C and E2C(R2) are accepted	DLP n regul during	Submission method for post-marketing periodic reports to CAs			
Australia	Only required for medicines for which conditions have been ...	ICH E2C	Annua years after t	Other requirements applicable to post-marketing periodic reports, if applicable			
Austria	In compliance with EU	In compliance with EU	In con	Regulatory Summary			
				Reference Document(s)			
				Electronic copy on a CD/DVD to: Centre National de Pharmacovigilance ...	Post authorisation safety study (PASS) might be requested by CNPM. En ...	Pharmacovigilance and Risk Management	Algerian Guidelines on Pharmacovigilance, Mar-2020
				Electronic: depto.snfvfg@anmat.gob.ar OR Paper: ANMAT Av. de Mayo 869, ...	Not applicable	Pharmacovigilance and Risk Management	Disposition 5358/2012: Approves the Good Pharmacovigilance ...
				Submit electronic file to the Pharmacovigilance and Special Access Br ...	Not applicable	Pharmacovigilance and Risk Management	Guideline: Pharmacovigilance Responsibilities of ...
				In compliance with EU	Not applicable	Pharmacovigilance and Risk Management	Law 153/2005: Amending the Austrian Drug Law, the Law on Prescription Obligation, the

# Dive Deep into PV requirements for a single country

## Regulatory Summaries

The screenshot shows the Cortellis Regulatory Summaries page. The 'Regulatory Summaries' tab is highlighted with a purple box. The 'China' link in the list of countries is also highlighted with a purple box.

**Cortellis™** Beth Wise

**Regulatory** CMC Intelligence

Drugs & Biologics Medical Devices & IVDs

All Comparison Tables Intelligence Reports **Regulatory Summaries** Source Documents

**Browse** Search

Filter by Country / Region

Drugs and Biologics Medical Devices and IVDs

**Authorities and Organizations**

- Competent Health Ministries and Regulatory Agencies | Country Sum
- European Institutions and Bodies | Overview
- European Heads of Medicines Agency | Overview

**International and Regional Bodies**

- Association of Southeast Asian Nations (ASEAN)
- Central American Integration System (SICA)
- Council for International Organizations of Medical Sciences (CIOMS)
- Council of Europe
- Eurasian Economic Union (EAEU)

**Medical Devices Regulatory Framework**

1. Click Regulatory Summaries

2. Scroll down to Pharmacovigilance and Risk Management Regulatory Requirements

3. Click China

### Pharmacovigilance and Risk Management Regulatory Requirements

Algeria, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, **China**, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, EAEU, Egypt, Estonia, European Union, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Indonesia, Iraq, Ireland, Israel, Italy, Japan, Jordan, Kenya, Latvia, Lebanon, Lithuania, Malaysia, Mexico, Morocco, Netherlands, New Zealand, Nigeria, Norway, Panama, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, USA, Ukraine, United Arab Emirates, United Kingdom, Venezuela, Vietnam

# Dive Deep into PV requirements for a single country

## Regulatory Summaries

The screenshot displays a software interface for viewing regulatory documents. On the left is a table of contents with items Q1 through Q9.1. The main area on the right shows the content for 'Q4 Post-marketing case reporting', specifically 'Q4.1 Expedited case reporting'. Under 'Q4.1.1 Is the reporting of domestic serious (unexpected, expected) ADRs to the Competent Authority/-ies required? If so, what is the timeline for reporting domestic serious (unexpected, expected) ADRs to the Competent Authority/-ies?', the answer is 'Yes' followed by a link to 'MOH Order No. 81: Provision for the Adverse Drug Reaction (ADR) Reporting and Monitoring. 04-May-2011'. Below this, a page number '17' is visible. The bottom section of the screenshot shows a snippet of text from 'IDRAC 46811' regarding reporting timelines for adverse drug reactions, with a link to 'NMPA Notification 2018/131: Issuance of Guidelines on Collection and Reporting of Cases of Drug Adverse Reactions, 19-Dec-2018'.

18 of 26 Automatic Zoom

**Q4 Post-marketing case reporting**

**Q4.1 Expedited case reporting**

**Q4.1.1 Is the reporting of domestic serious (unexpected, expected) ADRs to the Competent Authority/-ies required? If so, what is the timeline for reporting domestic serious (unexpected, expected) ADRs to the Competent Authority/-ies?**

Yes

According to [MOH Order No. 81: Provision for the Adverse Drug Reaction \(ADR\) Reporting and Monitoring. 04-May-2011](#) (IDRAC 124087), pharmaceutical manufacturers, drug distributors or medical institutions

17

*IDRAC 46811*

that discover or learn of a new or serious adverse drug reaction shall report it within 15 calendar days and shall report any deaths immediately

According to 5.2 of [NMPA Notification 2018/131: Issuance of Guidelines on Collection and Reporting of Cases of Drug Adverse Reactions, 19-Dec-2018](#) (IDRAC 288273), domestic serious adverse reaction occurring in China shall be reported within 15 calendar days from the date of discovery or knowledge of the serious adverse reaction. ADR leading to death, or a drug group adverse event/ADR shall be reported immediately; other ADR shall be reported within 30 calendar days.



1.Consistent Q&A format across all countries/regions provides expert guidance

2.Link to official documents

# Consult English translations - Cortellis translation

## Source Documents

**MOH Order No. 81: Provision for the Adverse Drug Reaction (ADR) Reporting and Monitoring, 04-May-2011**



1. All non-English official local documents (valid versions) have an English translation:

-Either Machine translation  
-or Cortellis translation  
-or Authority translation (official or unofficial)




2. You can easily identify the type of translation with the label below the document title.

3. Cortellis and Authority translations are provided at the top of the pdf documents, local version(s) underneath.

# Consult English translations - Machine translation

## Source Documents

**Guideline: UTS - Tracking and Surveillance Web Service Definitions, 16-Aug-2021**





1. All non-English official local documents (valid versions) have an English translation:

- Either Machine translation
- or Cortellis translation
- or Authority translation (official or unofficial)

2. You can easily identify the type of translation with the label below the document title.

3. Machine translations have an extra button above the local version pdf to open or download the machine translation.

# Track Risk Management Plans of products in the EU and US Intelligence Reports



1. Click Intelligence Reports

2. Scroll down to Product Approval Information and click on Risk Management System Tracker

Alternatively enter risk management in the search field at the top (next to country/region filter)

3. Click European Union or USA

4. In the Tracker click Download Excel



# Track Risk Management Plans of products in the EU and US

## Intelligence Reports (Excel spreadsheet - European Union)

	A	B	C	D	E	F
1	Link to Product Approval Document	Active Ingredient(s)	Name	Application Number	Dosage Form	Route of Administration
2	<a href="#">382716</a>	ramucirumab	CYRAMZA	EMA/H/C/002829 Rev. 17	Solution	Intravenous
3	<a href="#">382717</a>	tilmanocept	LYMPHOSEEK	EMA/H/C/002085 Rev. 8	Kit for radiopharmaceutical preparation	Intradermal ; Intratumoral ; Peritumoral ; Subcutaneous
4	<a href="#">382716</a>	abiraterone acetate	ABIRATERONE ACCORD	EMA/H/C/005408 Rev. 2	Tablet	Oral
5	<a href="#">382715</a>	tislelizumab	TEVIMBRA	EMA/H/C/005919 Rev. 2	Solution	Intravenous
6	<a href="#">382662</a>	hydrochlorothiazide ; telmisartan	KINZALKOMB	EMA/H/C/000415 Rev. 40	Tablet	Oral
	<a href="#">382661</a>	bevacizumab	ALYMSYS	EMA/H/C/005286 Rev. 8	Solution	Intravenous

1. Explore the product and risk management related data in the spreadsheet
2. Filter columns as desired
3. Link out to connected product approval documents and PRAC meetings

	Q	R	S	T	U	
	Reason(s) on list of additional monitoring (	PRAC meeting	Identified Risk	Potential Risk	Risk Missing Information	RMiM
	Not applicable	<a href="#">356344</a>	- Arterial thromboembolic events - Gastrointestinal perforation - Serious haemorrhagic events - Liver failure/liver injury (including hepatic encephalopathy in patients with HCC)	- Serious infection secondary to neutropenia - Posterior reversible encephalopathy syndrome - Severe clinical outcomes of venous thromboembolic events - Reproductive and developmental toxicity	Not Applicable	No
	Not applicable	<a href="#">377391</a>	None	Failure to detect the sentinel lymph node due to medication errors	Use in Patients receiving more than one dose	No
	Not applicable	<a href="#">318661</a>	None	None	None	No
	New active substance ; New biological	<a href="#">370415</a>	Immune-mediated adverse reactions	Reproductive and developmental toxicity	None	Yes
	Not applicable	<a href="#">377391</a>	Not Applicable	Not Applicable	Not Applicable	No
	New biological	<a href="#">353479</a>	None	None	None	No



# Identifying and monitoring official documents

## Using Quick Search\* and setting up Alerts

Quick Search

Quick search English keywords

Search

Advanced search

Filter

Country/Region Topic Document Type Document Category Date Translation Status All other filters

Reset Filters

Information Note (88) Announcement (63) Law (53) Form (39) Decree (37) Questions & Answers (22) Press Release (18) Instructions (16) Regulation (14) Guideline (13)

Checklist (6) Report (6) Expert Report (3) Letter (3) Ordinance (3) Recommendation (2) Inspection Report (1) Pharmacovigilance Bulletin (1)

Cancel Apply

Side by Side Viewer

Showing 1-5 of 5 results

Customize Columns

Sorted by Relevance

	Summary	Title	Document Category	Topic	Medical Device Specialty	Document Type
<input checked="" type="checkbox"/>	06-Feb-2023 V DE	ZLG: Diagram of and Guidelines on Communication Interfaces of Involved Authorities and Agencies in Case of Recalls and Rapid-Alert Notifications of C	Reference Document	Authorities and Organizations	N/A	Guideline
<input checked="" type="checkbox"/>	11-Apr-2019 V DE	BfArM and PEI Guideline: Joint Pilot Project between Federal Authorities and Ethics Committees for the "Processing of Applications for Clinical Trial	Reference Document	Product		
<input checked="" type="checkbox"/>	12-Jul-2016 V DE	Federal Ministry of Health (BMG): Position Paper of the Federal Ministry of Health on the Revision of the European Directive concerning Medical Devic	Reference Document	Manufa		
<input checked="" type="checkbox"/>	20-Apr-2017 V DE	BfArM: Submission Guide for Compassionate Use Programs, Version 1.3, 20-Apr-2017	Reference Document	Dossier Format and Submis...	N/A	Guideline
<input checked="" type="checkbox"/>	21-Jan-1994 V DE	Guidance for Studies Validating the Viral Safety of Medicinal Products Derived from Human Blood and Plasma - 21-Jan-1994	Reference Document	Pharmacovigilance Techn...	N/A	Guideline

1.Run search by selecting terms (country, topic, document types etc.) from filters as desired. Click Apply after selecting a filter.

2.Click Search

Save and Alert on

Query Reports

\*Quick Search supports English keywords only

- Searches through all Cortellis regulatory documents (including Regulatory Summaries and Intelligence Reports)
- Searches the title, abstract, reason for update and indexing fields (all provided in English)

3.To set up Alerts click the Alert icon and select

4.Follow the prompts in Alert pop-up as it and click Save

Save Search Query

Title PV Guidelines

Details

Query NOT asdfasdasdf

Content Set Regulatory

Filters 2 Filters Applied

Create Alert

Format HTML Text

Frequency Daily

Share beth.wise@clarivate.com

Cancel Save

# Identifying and monitoring official documents

## Using Source Documents Search\* and setting up Alerts

Search

"qualified person" Search Advanced search

Filter

Document Type Country/Region Topic Date Translation Status Medical Devices Specialty All other filters Reset Filters

Germany

Showing 1-10 of 44 results

Customize Columns Sorted by Relevance

Summary	Title	Country/Region	Language(s)	IDRAC Number	Product Category
<input checked="" type="checkbox"/> 17-Jun-2003 V DE DE RD	Decree of 17-Jun-2003: on the Permission of Exceptions to the Drug Law's Instructions With Regard to the Defense of Civilians and Prevention of Disas	Germany	German	39832	Drugs and Biologics
<input checked="" type="checkbox"/> 12-Dec-2016 V DE DE RD	Decree of 17-Jun-2003: on the Permission of Exceptions to the Drug Law's Instructions With Regard to the Defense of Civilians and Prevention of Disas	Germany	German	53314	Drugs and Biologics
<input checked="" type="checkbox"/> 29-Aug-2005 V DE EN,DE RD	Drug Law: 14th Amendment, 29-Aug-2005 (German and English Versions)	Germany	English German	52449	Drugs and Biologics Medical Devices and

1. Enter your search term(s)

2. Add filters as desired

3. Click Search

\*Source Documents Search supports English and local language keywords

- Searches local source/reference documents only
- Searches entire documents including pdf full text („Search in any language anywhere“)

Save and Alert on

Query Reports

Save Search Query

Title PV Guidelines

Query NOT asdfasdasdf

Content Set Regulatory

Filters 2 Filters Applied

Create Alert

Format HTML Text Frequency Daily

Share

beth.wise@clarivate.com Add more emails separated by (,) com

Cancel Save


3. To set up Alerts click the Alert icon and select Query

4. Follow the prompts in the Alert pop-up as it appears and click Save



Coming soon:  
**Cortellis AI Regulatory Assistant**

# An AI assistant to simplify your access to regulatory information



## A transformative AI partner you can trust

Proven and trusted AI rolled out across Clarivate industry-leading solutions (including Web of Science), used by:

- 3,050+ institutions and life sciences companies
- 1.85M+ queries submitted

**“We particularly appreciated the obvious care, time and caution in which Clarivate went about developing its AI products.”**

The Information Advisors Guide to Internet Research, Vol. 36, 2024

# Regulatory AI assistant to simplify your access to regulatory information


**Two use cases available at launch Sept 2025:**

## **Understand a requirement**

“What is the requirement for retaining records in clinical trials in the US?”

## **Find a document**

“Find me a document about the distribution of drug samples in Canada”



*Disclaimer: conceptual mock-ups for illustrative purposes only; final designs and functionality subject to change*

# Regulatory AI assistant to simplify your access to regulatory information

## Beta test example


### Understand a requirement:

What is the requirement for  
ADR Reporting (in Mexico)?

### Hi Claudia, what is your regulatory question?

Let me find answers from our high-quality, comprehensive, and verified regulatory data

**You can currently ask me to...** 📘 Question tips


 **Understand a requirement**

For example: "What is the requirement for retaining records in clinical trials in the US?"



# Regulatory AI assistant to simplify your access to regulatory information

- Answers provided in text format
- Includes links to Source Documents
- Feedback rating – thumbs up or down or add more detail via free text



Disclaimer: conceptual mock-ups for illustrative purposes only; final designs and functionality subject to change

# Regulatory AI assistant to simplify your access to regulatory information


## Beta test example

### Understand a requirement:


What is the requirement for risk management for a device in Turkey?

## Hi Claudia, what is your regulatory question?

Let me find answers from our high-quality, comprehensive, and verified regulatory data



**You can currently ask me to...** [Question tips](#)

 **Understand a requirement**

For example: "What is the requirement for retaining records in clinical trials in the US?"

# Regulatory AI assistant to simplify your access to regulatory information


- Answers provided in text format
- Includes links to Source Documents
- Feedback rating – thumbs up or down or add more detail via free text

The screenshot displays the Regulatory AI Assistant interface. At the top, there is a dark header with a search icon and the text "Regulatory Search", and a button labeled "Regulatory Assistant" with a "Beta" badge. Below the header, a light blue box contains the user's query: "What is the requirement for risk management for a device in Turkey?". The answer is presented in a white box with a blue star icon and the heading "Answer". The text of the answer states: "Risk management for medical devices in Turkey requires the application of the TS EN ISO 14971 standard. This standard outlines a process for manufacturers to identify hazards associated with medical devices (including in vitro diagnostic devices), estimate and evaluate the associated risks, implement controls to mitigate these risks, and monitor the effectiveness of these controls. Compliance with this standard is necessary for risk management activities related to medical devices in Turkey [Medical Devices Regulatory Framework](#) (Q12.6).". Below the answer, there is a section titled "Source documents" which lists two documents: "Medical Devices Regulatory Framework" (Expert Report • Cortellis • Turkey • Last updated 28-Apr-2025 • [More info](#)) and "Regulation on Active Implantable Medical Devices, 07-Jun-2011 (Turkish and English Versions)" (Regulation • TITCK • Turkey • Last updated 15-Mar-2017 • [More info](#)). At the bottom of the answer box are icons for thumbs up, thumbs down, and a speech bubble. Below the answer box is a text input field with the placeholder "Type your follow-up message" and a send button with an upward arrow. At the very bottom, there is a footer with the text "AI-generated content: check for accuracy • About Regulatory Assistant • Legal".

Disclaimer: conceptual mock-ups for illustrative purposes only; final designs and functionality subject to change

# Vision and roadmap

Harnessing generative AI to fuel your regulatory strategy and compliance



# How does the Regulatory Assistant work?

Understand user intent & context



Plan path to execution



Collect data from sources



Execute



Validate & enhance outputs



Iterate & refine



**Trusted Cortellis human curated content & original sources**

**Clarivate expert regulatory knowledge**

**Clarivate AI platform expertise**

## **Fast, accurate and hassle-free:**

- Full conversational experience
- Smooth entry point to Cortellis Regulatory Intelligence
- Search support for non-frequent users
- Ability to answer questions based on trusted sources - and refer back to them

# Wrap-Up and Feedback

What did you learn about today that will have a great impact on your work?

- Compare pre- and post-marketing PV and Med Dev incidence reporting requirements across multiple countries.
- Monitor Risk Management Plans for products in the European Union and the United States.
- The new AI Regulatory Assistant once launched.


# Get assistance with Cortellis

In-product guidance to assist you with your questions


- Click at the Support Center button at the bottom of the screen

If not visible, please enable functional cookies under "Manage cookie preferences".

[Manage cookie preferences](#)



- Help & contact us - contact Customer Care
- Guided tours - walk through the Cortellis platform
- Training resources - recorded trainings, Quick guides and short videos
- Ask the Expert (on Regulatory homepage)







# Thank you! Questions?

**Claudia Haas and Beth Wise**

Claudia.Haas@Clarivate.com and Beth.Wise@Clarivate.com

## About Clarivate

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit [clarivate.com](https://clarivate.com)

## © 2025 Clarivate

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.